Since publication of the original Schizophrenia Patient Outcomes Research Team (PORT)
treatment recommendations in 1998, considerable scientific advances have occurred in our …

Relapse in patients with schizophrenia has devastating repercussions, including worsening
symptoms, impaired functioning, cognitive deterioration and reduced quality of life. This …

Background: This double-blind, parallel-group, multicenter, phase-3 study was designed to
test the noninferiority of paliperidone palmitate 3-month formulation (PP3M) to the currently …

CONVENTIONAL ANTIPSYCHOTIC DRUGS, used for a half century to treat a range of major
psychiatric disorders, are being replaced in clinical practice by modern “atypical” …

Objective: Deficits in social functioning are a core feature of schizophrenia. Method: A
literature search of English language articles published between January 1990 and …

OBJECTIVE: The authors performed a systematic review and meta-analysis of studies of the
potential of new-generation antipsychotic drugs to improve adherence and decrease …

Objectives: The purpose of this paper is to review the literature since 1970 documenting the
effects of antipsychotic agents on serum lipids, including a discussion of possible …

OBJECTIVE: The authors assessed the efficacy and safety of the first long-acting atypical
antipsychotic (long-acting injectable risperidone) in patients with schizophrenia. METHOD …

Background: Numerous publications have provided evidence for clinically important
metabolic adverse effects of antipsychotics, but there is no systematic evaluation as to …

OBJECTIVE: Few long-term studies have compared the efficacy and safety of typical and
atypical antipsychotic medications directly in patients with a first episode of psychosis who …